Revance Therapeutics, Inc.

RVNC
Aramic LLC v. Revance Therapeutics, Inc. et al., (Case No. 5:21-cv-09585), N.D. Cal.

On October 15, 2021, the U.S. Food and Drug Administration (FDA) issued a complete response letter (CRL) to Revance Therapeutics, Inc., citing deficiencies found during an inspection at the Company’s manufacturing facility for its wrinkle injection treatment, DaxibotulinumtoxinA.

Previously, shares of Revance Therapeutics fell over 25% in intraday trading on October 12, 2021 after Form 483 was posted to the FDA’s website. Shares fell over 30% in after hours trading on October 15, 2021 following news of the FDA letter.

Lead Plaintiff deadline
February 8, 2022
class period
November 25, 2019
to
October 11, 2021
Case Documents
No documents available. Contact us if you need a case document.